|
Thyroid carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
This includes frequently reported gene fusions such as CCDC6/RET (PTC1), PRKAR1A/RET (PTC2) and ETV6/NTRK3 , and gene fusions that are less common in thyroid cancer (TPM3/NTRK1, EML4/ALK and EML4/NTRK3).
|
30668525 |
2019 |
|
Thyroid carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
The majority of patients with advanced thyroid cancer had detectable ctDNA. ctDNA measurement may offer superiority over conventional markers in several scenarios: earlier detection of progression in MTC; as an alternative biomarker when conventional markers are not available; more rapid assessment of the disease status in response to targeted therapies, thereby potentially allowing prompter discontinuation of futile therapies.
|
30253333 |
2018 |
|
Thyroid carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
In this study, the neurotrophin tyrosine receptor kinase TrkA (also called NTRK1), the common neurotrophin receptor p75<sup>NTR</sup>, and the proneurotrophin receptor sortilin were analyzed with immunohistochemistry in a cohort of thyroid cancers (n = 128) and compared with adenomas and normal thyroid tissues (n = 62).
|
29037860 |
2018 |
|
Thyroid carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
On the basis of our experience with performing AMP on 986 clinical FFPE samples, we show its potential as both a robust clinical assay and a powerful discovery tool, which we used to identify new therapeutically important gene fusions: ARHGEF2-NTRK1 and CHTOP-NTRK1 in glioblastoma, MSN-ROS1, TRIM4-BRAF, VAMP2-NRG1, TPM3-NTRK1 and RUFY2-RET in lung cancer, FGFR2-CREB5 in cholangiocarcinoma and PPL-NTRK1 in thyroid carcinoma.
|
25384085 |
2014 |
|
Thyroid carcinoma
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
PTC, the most frequent thyroid carcinoma histotype, is associated with gene rearrangements that generate RET/PTC and TRK oncogenes and with BRAF-V600E and RAS gene mutations.
|
23132790 |
2013 |
|
Thyroid carcinoma
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Recent novel and promising findings include additional abnormalities in key pathways associated with thyroid tumorigenesis (RET-Ras-BRAF-MEK; RET-beta-cateinin; TRK-PI3K-AKT; and MDM-p53-PTEN), single-nucleotide polymorphisms associated with thyroid cancer susceptibility, epigenetic silencing, alternative splicing, and gene expression abnormalities.
|
19907326 |
2010 |
|
Thyroid carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Axl is a tyrosine kinase receptor and although it is expressed in malignancy such as leukemia, colon cancer, melanoma, endometrial, prostate and thyroid cancers, its role has not been completely elucidated yet and appears to be complex.
|
15605394 |
2005 |
|
Thyroid carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
To determine if TRK-T1 expression can cause thyroid cancer in vivo, we developed transgenic mice that express the human TRK-T1 fusion protein in the thyroid.
|
11126359 |
2000 |
|
Thyroid carcinoma
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Oncogenic rearrangements of the NTRK1 gene (also designated TRKA), encoding one of the receptors for the nerve growth factor, are frequently detected in thyroid carcinomas.
|
7565764 |
1995 |